Headquartered in North Chesterfield, VA Fiscal year ends December NASDAQ: INDV indivior.com
Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) is a specialty biopharmaceutical company focused on developing and commercializing treatments for opioid use disorder (OUD) and other substance use disorders. Its flagship product, SUBLOCADE, is a long-acting injectable (LAI) buprenorphine treatment for moderate to severe OUD that has been prescribed to over 545,000 U.S. patients since launch. The company also markets sublingual buprenorphine products (including SUBOXONE Film) and PERSERIS, a long-acting injectable risperidone for schizophrenia, though PERSERIS marketing and promotion activities were discontinued in 2024. Indivior has announced a definitive all-stock merger-of-equals agreement with Supernus Pharmaceuticals to create a diversified, scaled, CNS-focused biopharmaceutical company, with the transaction expected to close in Q4 2026. The company generates approximately 87% of its revenue from U.S. operations, with the remainder from international markets. Updated
Howard Marks just filed five equity positions that look nothing like a bull-market portfolio, and every one has moved sharply since he bought. The question now is whether his thesis still holds…
Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) is a specialty biopharmaceutical company focused on developing and commercializing treatments for opioid use disorder (OUD) and other substance use disorders.
24/7 Wall St.'s 12-month price target for INDV is $48.72, rated Buy. The Wall Street consensus target is $49.00. INDV price prediction →
